• Proteoform-Specific Drug Interactions in Native Signaling

  2026-10-09

  Lutomski et al. developed a native mass-spectrometry workflow that connects membrane-protein post-translational modifications with ligand interactions in an undisturbed lipid environment. The study revealed proteoform-dependent behavior in rhodopsin, G proteins, and retinal PDE6, showing why conventional assays may overlook clinically relevant differences in drug selectivity.

• Injectable Gel Adhesive for Hemostasis and Infection

  2026-10-09

  The reference study presents a GelMA/QCS/Ca2+ double-network adhesive designed to address two linked emergency-care problems: non-compressible bleeding and bacterial wound contamination. In mouse models, the blue-light-triggered material showed rapid vessel-sealing and antibacterial performance, although its evidence remains preclinical and model-dependent.

• Gepotidacin: Clinical Evidence and Research Context

  2026-10-08

  Gepotidacin, also known as GSK2140944, is a first-in-class antibacterial evaluated in the phase 3 EAGLE-1 trial for uncomplicated urogenital gonorrhoea. This overview compares its mechanistic rationale with clinical evidence, emphasizing study limitations, population boundaries, safety findings and open questions for antibacterial research.

• Doxorubicin, Persister Cells, and Ferroptosis

  2026-10-08

  Doxorubicin research is often interpreted through DNA damage and apoptosis, but persister-cell biology adds a critical metabolic dimension. This article examines how lipid remodeling, mitochondria, and ferroptosis sensitivity can refine interpretation of Adriamycin responses without conflating distinct forms of cell death.

• SIS3 (Smad3 Inhibitor): Evidence and Limits

  2026-10-07

  SIS3 is a Smad3 inhibitor used to interrogate TGF-β signaling in preclinical research. Evidence from an osteoarthritis study supports reduced ADAMTS-5 expression after Smad3 inhibition, while renal fibrosis and diabetic nephropathy claims remain vendor-reported and require model-specific validation.

• Biotin-XX Tyramide Reagent: Evidence & Applications

  2026-10-06

  A source-grounded overview of Biotin-XX Tyramide Reagent, its reported role in tyramide signal amplification, and how it may conceptually support studies of cell-surface biology. The article separates supplier descriptions from peer-reviewed evidence and explains why findings from a Drosophila stem-cell migration study should not be treated as validation of the reagent itself.

• Gepotidacin’s Distinct Gyrase Mechanism

  2026-10-06

  Gibson and colleagues combined biochemical assays, competition experiments, and high-resolution structures to show that gepotidacin inhibits Staphylococcus aureus gyrase through a mechanism distinct from that of fluoroquinolones. The study links potent catalytic inhibition to persistent, predominantly single-stranded DNA cleavage complexes, offering a mechanistic framework for antibacterial discovery without implying clinical efficacy on its own.

• Dasatinib: Interpreting Kinase Evidence in Cancer Models

  2026-10-05

  Dasatinib and BMS-354825 illustrate why kinase-inhibitor findings must be interpreted by target, model, and endpoint. This article connects Src and Bcr-Abl biology with FAK signaling, metastatic phenotypes, and the SNAI1–PIK3R2/p-EphA2 evidence framework without treating distinct cancer models as interchangeable.

• N3-kethoxal: Evidence, Scope and Key Questions

  2026-10-05

  A source-grounded overview of how N3-kethoxal is described as a guanine-reactive nucleic acid probe, what its signals may mean, and where current evidence is insufficient. The discussion separates supplier claims from independently demonstrated findings and avoids treating catalog descriptions as validated biological performance data.

• TUNEL Evidence in RHO P347L Retinal Degeneration

  2026-10-04

  A source-grounded overview of how TUNEL-based DNA-fragmentation detection could complement the 2026 RHO P347L retinitis pigmentosa study, while distinguishing apoptosis-associated signals from direct evidence of trafficking defects, mitochondrial stress, and disease mechanism.

• Doxorubicin: Reading Cardiotoxicity Evidence

  2026-10-03

  Doxorubicin, also known as Adriamycin, is more than a DNA-damaging cancer chemotherapy drug. This evidence-led analysis examines how the NRF2–HIPK2 findings in doxorubicin-induced cardiotoxicity refine interpretation of tumor efficacy, cardiac injury, autophagy, and apoptosis.

• AAL-993: From VEGFR Blockade to Translation

  2026-10-01

  A mechanistic and translational guide to using AAL-993 as a VEGF receptor inhibitor in angiogenesis, melanoma, and pathway-linked tumor research.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-10-01

  Zhao and colleagues present a standardized whole-blood stimulation protocol that combines defined immune challenges with metabolic perturbation and cytokine quantification. The approach preserves the multicellular blood environment while improving comparability for cohort-scale studies of how metabolic pathways shape immune responses.

• CD44 Rewires Metabolism in IDH-Mutant Leukemia

  2026-10-01

  The reference study identifies CD44 as a functional metabolic dependency in IDH-mutant leukemia, linking pentose phosphate pathway activation and glycolytic suppression to NADPH-supported R-2HG production. Its isogenic CRISPR-based design suggests that combining CD44 disruption with mutant IDH inhibition may provide a rational strategy for overcoming incomplete responses and resistance.

• Midecamycin: Mechanism, MICs, and Glycosylation

  2026-09-30

  Midecamycin is an acetoxy-substituted macrolide antibiotic and bacterial protein synthesis inhibitor with strongest reported activity against selected Gram-positive bacteria. Its 23S rRNA mechanism is distinct from its resistance liability: glycosylation at the 2′-O inactivation site can abolish antimicrobial activity.

8450 records 1/564 page Next 12345 下5页 Last page